Efficacy and safety of combination therapy of tocilizumab and abatacept in patients with refractory systemic-onset juvenile idiopathic arthritis

Efficacy and safety of combination therapy of tocilizumab and abatacept in patients with refractory systemic-onset juvenile idiopathic arthritis - Efficacy and safety of combination therapy of tocilizumab and abatacept in patients with refractory systemic-onset juvenile idiopathic arthritis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024178

Enrollment

Registered

2016-09-28

Start date

2016-09-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic-onset juvenile idiopathic arthritis(sJIA)

Interventions

Tocilizumab 8mg/kg every 2 weeks, and Abatacept 10 mg/kg every 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients with a diagnosis of sJIA at childhood and with refractory arthritis 2 Patients gave written informed consent

Exclusion criteria

Exclusion criteria: 1 Pulmonary tuberculosis, active bacterial infection or deep mycotic infection 2 Infection of HIV, HCV, HBV 3 Administration of live vaccine within 4 weeks 4 Cardiac dysfunction 5 Pregnant subjects or subjects who do not agree with contraception during the study period

Design outcomes

Primary

Measure	Time frame
ACR pedi30 at week 24	—

Secondary

Measure	Time frame
Safety dose of corticosteroids biomarkers of disease activity(MMP-3, IL-6, and IL18) ultrasonography	—

Countries

Japan

Contacts

Public ContactAsami Oohara

Yokohama City University Hospital Pediatrics

asami_sherry@yahoo.co.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026